HTGC250516P20000
- 2.83
- 0.000.00%
Hercules Capital Newsroom
Express News | Altimmune Inc - Pemvidutide Phase 2B Trial Data Expected Q2 2025
Express News | Axsome Therapeutics: Retired Its Previous Term Loan With Hercules Capital
Express News | Altimmune Secures up to $100 Million in Credit Facility From Hercules Capital
Press Release: Altimmune Secures Up to $100 Million in Credit Facility From Hercules Capital
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
Hercules Capital To Go Ex-Dividend On May 13th, 2025 With 0.4 USD Dividend Per Share And 0.07 USD Special Dividend Per Share
Investing in Hercules Capital (NYSE:HTGC) Five Years Ago Would Have Delivered You a 187% Gain
Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders
Compass Point Maintains Hercules Capital(HTGC.US) With Hold Rating, Maintains Target Price $18
Hercules Capital, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Wells Fargo Maintains Hercules Capital(HTGC.US) With Buy Rating, Cuts Target Price to $19
KBW Maintains Hercules Capital(HTGC.US) With Buy Rating, Maintains Target Price $20.5
Piper Sandler Maintains Hercules Capital(HTGC.US) With Buy Rating, Maintains Target Price $20
Piper Sandler Sticks to Their Buy Rating for Hercules Capital (HTGC)
Analysts' Opinions Are Mixed on These Financial Stocks: TFS Financial (TFSL), Hercules Capital (HTGC) and Webster Financial (WBS)
Hercules Capital: Strong Market Position and Growth Potential Reinforce Buy Rating
Hercules Capital, Inc. (HTGC) Q1 2025 Earnings Call Transcript Summary
Hercules Capital: 1Q Over $5.0B of Assets Under Management, an Increase of 11.0% Yr-over-Yr >HTGC
Hercules Capital: Conservative Balance Sheet Management With Net GAAP Leverage of 97.4% and Net Regulatory Leverage of 82.7% >HTGC
8-K: Hercules Capital Reports First Quarter 2025 Financial Results